Introduction
The eradication of Helicobacter pylori cures gastritis, markedly reduces the frequency of ulcer relapse, reduces the risk of gastric adenocarcinoma and leads to regression of MALT lymphoma. 1 Unfortunately, resistance to the standard therapeutic antimicrobial agents used for treatment (clarithromycin, metronidazole, amoxycillin and tetracycline) has been demonstrated, 2 so new treatment options must be sought. 1 An essential step in the search for effective antimicrobial agents for the treatment of H. pylori infection is to examine the in vitro activity of antibiotics commonly used for other infections or that of new recently marketed or non-marketed antimicrobial agents. In the study reported here we determined the in vitro activities of: mupirocin, a topical antimicrobial agent successfully used for staphylococcal infections of the skin; 3 the injectable streptogramin quinupristin-dalfopristin (RP 59,500), which has good activity against multi-resistant Gram-positive microorganisms; the non-marketed oxazolidinones linezolid (U-100766) and eperezolid (U-100592); and the nonmarketed fluoroquinolones sitafloxacin, clinafloxacin and moxifloxacin, in comparison with those of amoxycillin, clarithromycin, metronidazole and ciprofloxacin against 57 H. pylori strains.
Mupirocin was included in our study because it has properties that may make it a good candidate for use in gastric H. pylori infections. These include: its unique chemical structure and mode of action (it acts as a competitive inhibitor of the enzyme isoleucyl tRNA synthetase); lack of cross-resistance to existing antimicrobial agents; 3 stability and higher activity at acid pH against bacteria included in its spectrum; 3 good penetration into the superficial layers of the skin and nasal mucosa, and into a relatively acidic medium with proteins in purulent exudates after topical delivery; 3 and water solubility. Important ecological features include extensive degradation to the antibacterially inactive metabolite, monic acid, by hepatic and renal esterases and low activity against normal members of the faecal flora such as enterococci, anaerobes and enterobacteria. 3 In vitro and in vivo studies of mupirocin derivatives have shown that, compared with mupirocin, they have better potency and spectrum of activity, and superior pharmacokinetics; they also seem to be non-toxic, non-sensitizing in animals and humans, and free of teratogenic or mutagenic potential.
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Materials and methods
All strains of H. pylori tested were obtained from human gastric biopsies taken by endoscopy. Biopsies were inoculated on to HPA medium 4 and the microorganisms were identified by morphology, urease production and catalase and oxidase activity. The strains were stored at -80ЊC in brain-heart infusion broth (Oxoid, Basingstoke, UK) con- 5 using Mueller-Hinton agar (Oxoid) supplemented with 10% sheep blood. Antibiotic concentrations ranged from 128 to 0.008 mg/L. The agar plates were inoculated with a Steers replicator. The inoculum was prepared in sterile saline from subcultures on brain-heart infusion agar supplemented with 10% sheep blood and diluted so that the turbidity was equal to that of a 1 McFarland standard. The final inoculum was approximately 5 ϫ 10 5 cfu/spot. Test plates were incubated at 35ЊC for 72 h in gas jars with Campylobacter gas-generating sachets (Oxoid). Influence of a low pH on the activity of the most active antimicrobial agents was also determined. Mueller-Hinton agar (Oxoid) supplemented with 10% sheep blood with a pH of 5.4 was prepared by adding HCl after sterilization. The pH was measured with a surface pH meter (CRISON micropH 2002) after solidification of the agar and before inoculation of the agar plates. The MIC was defined as the lowest concentration of antimicrobial agent that completely inhibited growth, disregarding a single colony or a faint haze caused by the inoculum. Bacteria were considered resistant when the MIC was у8 mg/L for metronidazole and у4 mg/L for clarithromycin. For amoxycillin, NCCLS recommendations 5 were followed and, for mupirocin, a breakpoint of у8 mg/L was used. 6 
Susceptibility of
Results and discussion
The MICs of the antimicrobial agents at pH 7.4 are shown in the Table. Three strains (5.5%) were resistant to clarithromycin, and 12 strains (31.6%), including two clarithromycin-resistant strains, were resistant to metronidazole. Amoxycillin was active against all of the isolates. The most active fluoroquinolone was sitafloxacin (р0.008-0.03 mg/L). The MIC 90 of this quinolone (р0.008 mg/L) was 15-fold lower than that of clinafloxacin (0.12 mg/L) and >128-fold lower than that of ciprofloxacin and moxifloxacin (2 mg/L). The activity of mupirocin, clinafloxacin and sitafloxacin was also determined at pH 5.4. The activity of mupirocin at pH 5.4 (range р0.008-0.12 mg/L, MIC 50 0.03 mg/L, MIC 90 0.12 mg/L) was twice that at pH 7.4, but the activity of clinafloxacin and sitafloxacin was the same at pH 5.4 and 7.4.
Our results on the in vitro susceptibility of H. pylori to amoxycillin, clarithromycin and metronidazole are in agreement with those of other authors. 2 All strains were susceptible to amoxycillin, and the incidence of resistance to metronidazole, clarithromycin and both metronidazole and clarithromycin were consistent with a previous report. 2 Mupirocin was very active against H. pylori at both pH values tested. Intragastric pH is an important limiting factor for the stability and activity of most antibiotics used for treating H. pylori infection. In the present study, MICs of mupirocin were lower at pH 5.4, suggesting that mupirocin would be especially suitable for use in the acidic environment of the stomach. None of the strains tested exhibited resistance to mupirocin, in contrast to that observed with 284 Sitafloxacin was the most active fluoroquinolone tested (MIC 90 р 0.008 mg/L), while ciprofloxacin and moxifloxacin (MIC 90 s 2 mg/L) were the least active. From our results, the activity of sitafloxacin is greater than that reported for HSR-903, a new quinolone which is very active against H. pylori. 7 The activity of clinafloxacin (MIC 90 0.12 mg/L), while lower than that reported for HSR-903, 7 was higher than that of moxifloxacin and ciprofloxacin, antibiotics with a similar activity against this microorganism. In another study, 8 activities of moxifloxacin and clinafloxacin have been shown to be four times that of ciprofloxacin. The enhanced activity of sitafloxacin and clinafloxacin against H. pylori is in accordance with the reported higher activity against different pathogens of the fluoroquinolones with a fluorine at position X 8 .
There are no data on the activity of quinupristin-dalfopristin (RP 59,500) against H. pylori. According to a previously used susceptibility breakpoint (2 mg/L), 9 our results show that quinupristin-dalfopristin has a low activity (MIC 90 4 mg/L) against this microorganism. The oxazolidinones linezolid and eperezolid are a novel class of oral and parenteral compounds. 10 The tentative interpretative breakpoint (4 mg/L) 10 would predict low susceptibility of H. pylori to these antimicrobial agents.
